Antioxidant pill shows promise in slowing blindness

NCT ID NCT05537220

Ongoing Disease control Sponsor: Johns Hopkins University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests whether an oral antioxidant called N-acetylcysteine (NAC) can slow the loss of vision in people with retinitis pigmentosa, an inherited eye disease that causes gradual blindness. About 485 adults aged 18 to 65 are taking NAC or a placebo for several years. The goal is to see if NAC protects the light-sensing cells in the retina and preserves side and night vision.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

retinitis pigmentosa Usher syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RETINITIS PIGMENTOSA

Contacts and locations

Locations

Emory University, Emory Eye Center

Atlanta, Georgia, 30322, United States
Harvard University, Mass. Eye and Ear

Boston, Massachusetts, 02114, United States
Mayo Clinic, Department of Ophthalmology

Rochester, Minnesota, 55905, United States
McGill University, The Research Institute of the McGill University Health Center

Montreal, Quebec, H4A 3J1, Canada
Medical College of Wisconsin, The Eye Institute

Milwaukee, Wisconsin, 53226, United States
Medical University of Graz, Department of Ophthalmology

Graz, Styria, 8036, Austria
Northwestern University

Evanston, Illinois, 60208, United States
Radboud University, Radboud University Medical Centre

Nijmegen, Gelderland, 6500 HB, Netherlands
Retina Foundation of the Southwest

Dallas, Texas, 75231, United States
Scheie Eye Institute

Philadelphia, Pennsylvania, 19104, United States
Stanford University, Byers Eye Institute

Stanford, California, 94303, United States
University College London, Moorfields Eye Hospital

London, England, United Kingdom
University Of Illinois At Chicago

Chicago, Illinois, 60612, United States
University of Amsterdam, Amsterdam Medical Center

Amsterdam, Northern Holland, 1105 AZ, Netherlands
University of California - Davis, Department of Ophthalmology & Vision Science

Davis, California, 95817, United States
University of California - San Francisco, Department of Ophthalmology

San Francisco, California, 94158, United States
University of Florida - Jacksonville, UF Health Jacksonville

Jacksonville, Florida, 32209, United States
University of Iowa, Carver College of Medicine

Iowa City, Iowa, 52242, United States
University of Miami, Bascom Palmer Eye Institute

Miami, Florida, 33136, United States
University of Michigan, Kellogg Eye Center

Ann Arbor, Michigan, 48105, United States
University of Minnesota, Department of Ophthalmology and Visual Neurosciences

Minneapolis, Minnesota, 55455, United States
University of Oklahoma, Dean McGee Eye Institute

Oklahoma City, Oklahoma, 73104, United States
University of Southern California, Keck School of Medicine

Los Angeles, California, 90089, United States
University of Tübingen, Department für Augenheilkunde

Tübingen, Baden-Wurttemberg, 72076, Germany
University of Utah, Moran Eye Center

Salt Lake City, Utah, 84132, United States
University of Washington, Department of Ophthalmology

Seattle, Washington, 98109, United States
University of Wisconsin - Madison, McPherson Eye Research Institute

Madison, Wisconsin, 53705, United States
Universitätsspital Basel, Eye Clinic

Basel, CH-4031, Switzerland
Vanderbilt University, Vanderbilt Eye Institute

Nashville, Tennessee, 37211, United States
Vitreo Retinal Associates

Gainesville, Florida, 32607, United States
Wilmer Eye Institute- Johns Hopkins University

Baltimore, Maryland, 21287, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.